Fecal calprotectin;Calprotectina fecal

Revista Espanola de Enfermedades Digestivas

Volumn 99, Issue 12, 2007, Pages 683-688

  Rodrigo, L ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

BACTERIOSTASIS; CELIAC DISEASE; COLITIS; COLON CROHN DISEASE; COLON DIVERTICULOSIS; COLONOSCOPY; COLORECTAL CARCINOMA; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EDITORIAL; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FUNGICIDAL ACTIVITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GRANULOCYTOSIS; HUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; REFERENCE VALUE; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 40949164270     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (33)

1. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993; 34: 1357-63.
2. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol 1992; 27: 793-8.
3. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32: 171-7.
4. Fagerberg UL, Lööf L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003; 37: 468-72.
5. Bjarnason I, Sherwood R. Fecal calprotectin: A significant step in the non-invasive assessment of intestinal inflammation. J Pediatr Gastroenterol Nutr 2001; 33: 11-3.
6. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel diseases. J Pediatr Gastroenterol Nutr 2001; 33: 14-22.
7. Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: A marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 841-5.
8. Tøn H, Brandsnes O, Dale S, Holtlund J, Skuibina E, Schjønsby H, et al. Improved assay for fecal calprotectin. Clin Chem Acta 2000; 292: 41-54.
9. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labeled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-4.
10. Campeotto F, Butel MJ, Kalach N, Derrieux S, Aubert-Jacquin C, Barbot L, et al. High fecal calprotectin concentrations in newborn infants. Arch Dis Child Fetal Neonatal Ed 2004; 89: F353-F354.
11. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut 2006; 55: 426-31.
12. Gisbert JP, González-Lama Y, Maté J. Utilidad de los marcadores biológicos en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2007; 30: 117-29.
13. Sánchez Lombraña JL, Palacio MA, Carbajal C, Vivas S, Pérez R, Rodrigo L. Marcadores biológicos de actividad en la enfermedad inflamatoria intestinal crónica. Rev Esp Enferm Dig 1997; 89: 855-8.
14. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56 : 1394-403.
15. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-13.
16. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-60.
17. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003; 49 (6 Pt 1): 861-7.
18. Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms.J Pediatr Gastroenterol Nutr. 2005; 40: 450-5.
19. Bonnin Tomás A, Vila Vidal M, Rosell Camps A. Calprotectina fecal como marcador diferencial entre patología gastrointestinal orgánica y funcional. Rev Esp Enferm Dig 2007; 99: 689-93.
20. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 14-22.
21. Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-13.
22. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000; 95: 2831-7.
23. Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 2004; 36: 467-70.
24. Montalto M, Santoro L, Curigliano V, et al. Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol 2007; 42: 957-61.
25. Yagmur E, Schnyder B, Scholten D, et al. Elevated concentrations of fecal calprotectin in patients with liver cirrhosis. Dtsch Med Wochenschr 2006; 131: 1930-4.
26. García Sánchez M del V, González R, Iglesias Flores E, et al. Valor diagnóstico de la calprotectina fecal para predecir una colonoscopia alterada. Med Clin (Barc) 2006; 127: 41-6.
27. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006; 41: 720-5.
28. Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, Van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990; 211: 622-7.
29. Stavlo PL, Libsch KD, Rodeberg DA, Moir CR. Pediatric ileal pouch-anal anastomosis: functional outcomes and quality of life. J Pediatr Surg 2003; 38: 935-9.
30. Thomas P, Rihani H, Røseth A, et al. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum 2000; 43: 214-20.
31. Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouchanal anastomosis. Gastroenterol 2004; 126: 1280-6.
32. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (Phi-Cal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: Comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004; 53: 1329-33.
33. Limburg PJ, Devens ME, Harrington JJ, Diehl NN, Mahoney DW, Ahlquist DA. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003; 98: 2299-305.